Janus Henderson Hrzn Biotec A2 USD

Performance History31/03/2024
Growth of 1,000 (EUR)
Janus Henderson Hrzn Biotec A2 USD
Fund48.02.02.519.19.6
+/-Cat28.75.015.318.05.9
+/-Idx22.2-4.95.69.2-0.4
 
Key Stats
NAV
25/04/2024
 USD 22.25
Day Change -3.02%
Morningstar Category™ Sector Equity Biotechnology
ISIN LU1897414303
Fund Size (Mil)
31/03/2024
 USD 261.80
Share Class Size (Mil)
24/04/2024
 USD 56.94
Max Initial Charge 5.00%
Ongoing Charge
14/02/2024
  1.89%
Investment Objective: Janus Henderson Hrzn Biotec A2 USD
The Sub-Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its net assets in equities or equity-related instruments of biotechnology and biotechnology-related companies worldwide.
Returns
Trailing Returns (EUR)25/04/2024
YTD1.47
3 Years Annualised7.90
5 Years Annualised16.53
10 Years Annualised-
12 Month Yield 0.00
Management
Manager Name
Start Date
Daniel Lyons
10/12/2018
Agustin Mohedas
31/01/2023
Click here to see others
Inception Date
10/12/2018
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TRMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Janus Henderson Hrzn Biotec A2 USD29/02/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks95.420.0095.42
Bonds0.000.000.00
Cash1.750.561.19
Other3.390.003.39
Top 5 Regions%
United States84.58
United Kingdom4.68
Eurozone4.37
Europe - ex Euro2.93
Asia - Emerging2.63
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Vertex Pharmaceuticals IncHealthcareHealthcare7.78
Amgen IncHealthcareHealthcare7.39
argenx SE ADRHealthcareHealthcare3.41
Ardelyx IncHealthcareHealthcare3.39
Sarepta Therapeutics IncHealthcareHealthcare3.12
Janus Henderson Hrzn Biotec A2 USD
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookie Settings        Disclosures